Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Mastocytosis, Systemic 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Esthesioneuroblastoma, Olfactory 1Emergence Delirium 1Delirium 1Cachexia 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Anus Neoplasms 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1enasidenib 1Tomography, X-Ray Computed 1Radionuclide Imaging 1Positron-Emission Tomography 1Ibuprofen 1Electrocardiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esthesioneuroblastoma, Olfactory × Ibuprofen × 1 year × Clear all
NCT05012098 2025-08-08

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 14 charts
CNS

Nose Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡